Childhood chronic myeloid leukemia with T315I mutation in ABL1 kinase domain: report of one case and review of literature
10.3760/cma.j.issn.1009-9921.2019.09.006
- VernacularTitle: 伴ABL1激酶区T315I突变儿童慢性粒细胞白血病一例并文献复习
- Author:
Lili PAN
1
;
Shaohua LE
;
Jian LI
;
Yongzhi ZHENG
Author Information
1. Department of Pediatric Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Blood Medicine Center, Fuzhou 350001, China
- Publication Type:Journal Article
- Keywords:
Leukemia, myeloid, chronic;
Mutation;
BCR-ABL fusion gene;
Tyrosine kinase inhibitor
- From:
Journal of Leukemia & Lymphoma
2019;28(9):538-540
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features and treatment of child patient with chronic myeloid leukemia (CML) and T315I mutation in the ABL1 kinase domain.
Methods:The clinical features, diagnosis and treatment of one child CML patient with T315I mutation in ABL1 kinase domain in Fujian Medical University Union Hospital were retrospectively analyzed, and the literature was reviewed.
Results:The patient was treated with imatinib and dasatinib. The BCR-ABLIS value decreased and then increased. The disease progressed to the accelerated phase. At the same time, the T315I mutation was detected in the ABL1 kinase domain, the harringtonine chemotherapy was used, and the condition of patient got better. But eventually the hematopoietic stem cell transplantation could not be performed, the CML progressed to the blast phase and the patient died half a year later.
Conclusions:The prognosis of children with CML and T315I mutation in ABL1 kinase domain is poor. In the absence of punatinib treatment, hematopoietic stem cell transplantation should be performed as soon as possible after chemotherapy, which may improve the prognosis.
